INT68202

From wiki-pain
Revision as of 08:57, 22 September 2012 by Daniel (Talk | contribs)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Context Info
Confidence 0.68
First Reported 1997
Last Reported 2010
Negated 0
Speculated 1
Reported most in Body
Documents 26
Total Number 27
Disease Relevance 23.15
Pain Relevance 5.18

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

small molecule metabolic process (ADA) aging (ADA) cytoplasm (ADA)
cytosol (ADA) extracellular space (ADA) cell adhesion (ADA)
Anatomy Link Frequency
visceral 3
CSF 3
natural killer cell 1
PBSC 1
kidney 1
ADA (Homo sapiens)
Pain Link Frequency Relevance Heat
Adalimumab 1267 100.00 Very High Very High Very High
adenocard 131 100.00 Very High Very High Very High
Infliximab 471 99.56 Very High Very High Very High
Multiple sclerosis 12 99.00 Very High Very High Very High
Central nervous system 18 98.60 Very High Very High Very High
Etanercept 13 97.88 Very High Very High Very High
Angina 1 95.56 Very High Very High Very High
cva 40 86.64 High High
headache 34 85.76 High High
rheumatoid arthritis 224 84.64 Quite High
Disease Link Frequency Relevance Heat
Severe Combined Immunodeficiency 12 100.00 Very High Very High Very High
Autoimmune Disease 14 99.92 Very High Very High Very High
Pleural Effusion 9 99.84 Very High Very High Very High
Lymphatic System Cancer 15 99.78 Very High Very High Very High
Listeria Meningitis 12 99.72 Very High Very High Very High
Demyelinating Disease 25 99.56 Very High Very High Very High
Meningitis 55 99.32 Very High Very High Very High
Fever 493 99.28 Very High Very High Very High
Mycobacterial Infection 266 99.22 Very High Very High Very High
Central Nervous System Disease 2 98.96 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
[A case of natural killer cell lymphoma with high adenosine deaminase level in pleural effusion].
Gene_expression (level) of adenosine deaminase in natural killer cell associated with pleural effusion, adenocard and lymphatic system cancer
1) Confidence 0.68 Published 2005 Journal Nihon Kokyuki Gakkai Zasshi Section Title Doc Link 15997786 Disease Relevance 1.43 Pain Relevance 0.19
Increased serum/plasma ADA activity, comprising both ADA-1 and ADA-2 activity, has been used as a biochemical marker for infectious diseases.22–24 Increased serum ADA has been reported in infectious diseases such as viral and bacterial pneumonia, HIV infection, extra-pulmonary and pulmonary tuberculosis, visceral leishmaniasis, and mononucleosis.21,22,25
Gene_expression (comprising) of ADA in visceral associated with leishmaniasis, mycobacterial infection, bacterial pneumonia, acquired immune deficiency syndrome or hiv infection, communicable diseases and infection
2) Confidence 0.63 Published 2010 Journal Clinics (Sao Paulo) Section Body Doc Link PMC2910858 Disease Relevance 1.49 Pain Relevance 0.11
Increased serum/plasma ADA activity, comprising both ADA-1 and ADA-2 activity, has been used as a biochemical marker for infectious diseases.22–24 Increased serum ADA has been reported in infectious diseases such as viral and bacterial pneumonia, HIV infection, extra-pulmonary and pulmonary tuberculosis, visceral leishmaniasis, and mononucleosis.21,22,25
Gene_expression (comprising) of ADA in visceral associated with leishmaniasis, mycobacterial infection, bacterial pneumonia, acquired immune deficiency syndrome or hiv infection, communicable diseases and infection
3) Confidence 0.63 Published 2010 Journal Clinics (Sao Paulo) Section Body Doc Link PMC2910858 Disease Relevance 1.49 Pain Relevance 0.10
Increased serum/plasma ADA activity, comprising both ADA-1 and ADA-2 activity, has been used as a biochemical marker for infectious diseases.22–24 Increased serum ADA has been reported in infectious diseases such as viral and bacterial pneumonia, HIV infection, extra-pulmonary and pulmonary tuberculosis, visceral leishmaniasis, and mononucleosis.21,22,25
Gene_expression (comprising) of ADA in visceral associated with leishmaniasis, mycobacterial infection, bacterial pneumonia, acquired immune deficiency syndrome or hiv infection, communicable diseases and infection
4) Confidence 0.63 Published 2010 Journal Clinics (Sao Paulo) Section Body Doc Link PMC2910858 Disease Relevance 1.44 Pain Relevance 0.11
In conclusion, we showed that ADA and XO levels were increased in patients with CCHF.
Gene_expression (levels) of ADA associated with fever
5) Confidence 0.63 Published 2010 Journal Clinics (Sao Paulo) Section Body Doc Link PMC2910858 Disease Relevance 1.05 Pain Relevance 0.10
ADA SCID is currently explained only by intracellular lymphotoxicity of accumulated adenosine.
Gene_expression (explained) of ADA associated with adenocard and severe combined immunodeficiency
6) Confidence 0.60 Published 1998 Journal Nippon Ika Daigaku Zasshi Section Abstract Doc Link 9808987 Disease Relevance 1.11 Pain Relevance 0.45
Patients received ADA 160/80 mg, followed by 80 mg every other week.
Gene_expression (received) of ADA associated with adalimumab
7) Confidence 0.57 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727899 Disease Relevance 1.00 Pain Relevance 0.39
Those in remission at both week 0 and week 4 (n = 55) were randomized to receive ADA 40 mg every other week (n = 19), ADA 40 mg weekly (n = 18), or placebo (n = 18), through 56 weeks.
Gene_expression (receive) of ADA associated with adalimumab
8) Confidence 0.57 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727899 Disease Relevance 0.14 Pain Relevance 0.37
There were no statistically significant differences between the two ADA dosages for any of these endpoints.
Gene_expression (dosages) of ADA associated with adalimumab
9) Confidence 0.57 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727899 Disease Relevance 0.05 Pain Relevance 0.32
Those in remission at both week 0 and week 4 (n = 55) were randomized to receive ADA 40 mg every other week (n = 19), ADA 40 mg weekly (n = 18), or placebo (n = 18), through 56 weeks.
Gene_expression (receive) of ADA associated with adalimumab
10) Confidence 0.57 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727899 Disease Relevance 0.14 Pain Relevance 0.39
Few data exist for ADA, but in CHARM a case of multiple sclerosis was reported in a patient treated with ADA (Colombel et al 2007a).
Gene_expression (exist) of ADA associated with multiple sclerosis and adalimumab
11) Confidence 0.57 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727899 Disease Relevance 1.07 Pain Relevance 0.66
The aim of the present study was to investigate the serum levels of ADA-2 (the main source of ADA activity in the serum, which plays crucial roles in immune function) and xanthine oxidase (which increases tissue damage via the formation of free oxygen radicals) in CCHF patients and to compare the results with those obtained for healthy controls.
Gene_expression (source) of ADA associated with fever
12) Confidence 0.56 Published 2010 Journal Clinics (Sao Paulo) Section Body Doc Link PMC2910858 Disease Relevance 0.91 Pain Relevance 0.05
The aim of the present study was to investigate the serum levels of ADA-2 (the main source of ADA activity in the serum, which plays crucial roles in immune function) and xanthine oxidase (which increases tissue damage via the formation of free oxygen radicals) in CCHF patients and to compare the results with those obtained for healthy controls.
Spec (investigate) Gene_expression (levels) of ADA associated with fever
13) Confidence 0.56 Published 2010 Journal Clinics (Sao Paulo) Section Body Doc Link PMC2910858 Disease Relevance 0.92 Pain Relevance 0.05
Serum ADA and XO levels in patients with CCHF were significantly higher than were those determined for the control group (p<0.05), whereas no significant association was observed between the serum ADA or XO level and the severity of disease in CCHF patients (p>0.05).
Gene_expression (levels) of Serum ADA associated with disease and fever
14) Confidence 0.55 Published 2010 Journal Clinics (Sao Paulo) Section Body Doc Link PMC2910858 Disease Relevance 1.39 Pain Relevance 0
ADA is produced in a mammalian cell expression system and is purified by a process that includes specific viral inactivation and removal steps.
Gene_expression (produced) of ADA associated with adalimumab
15) Confidence 0.51 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727899 Disease Relevance 0.59 Pain Relevance 0.41
The aim of the present study was to investigate the serum levels of ADA-2 (the main source of ADA activity in the serum, which plays crucial roles in immune function) and xanthine oxidase (which increases tissue damage via the formation of free oxygen radicals) in CCHF patients and to compare the results with those obtained for healthy controls.
Gene_expression (source) of ADA associated with fever
16) Confidence 0.49 Published 2010 Journal Clinics (Sao Paulo) Section Body Doc Link PMC2910858 Disease Relevance 0.91 Pain Relevance 0.05
Similarly increased CSF ADA levels have been reported in childhood TBM with adverse neurological outcome [27].
Gene_expression (levels) of ADA associated with mycobacterial infection
17) Confidence 0.45 Published 2006 Journal Cerebrospinal Fluid Res Section Body Doc Link PMC1448186 Disease Relevance 1.45 Pain Relevance 0.05
Approximately 3 ml of CSF was obtained; 2 ml of CSF was used for total and differential cell count, biochemistry, and smear for Gram's, India ink, and acid fast bacilli (AFB) staining and the remaining CSF was used for ADA estimation.
Gene_expression (estimation) of ADA
18) Confidence 0.45 Published 2006 Journal Cerebrospinal Fluid Res Section Body Doc Link PMC1448186 Disease Relevance 0.84 Pain Relevance 0.23
High levels of ADA in CSF have high sensitivity and high specificity for tuberculous meningitis, but there are some reports that high ADA levels in CSF in other meningitis.
Gene_expression (levels) of ADA in CSF associated with mycobacterial infection and meningitis
19) Confidence 0.30 Published 2009 Journal Rinsho Shinkeigaku Section Abstract Doc Link 19928691 Disease Relevance 0.85 Pain Relevance 0.16
This report suggests that listeria meningitis must be included in the differential diagnosis of high levels of ADA in CSF.
Gene_expression (levels) of ADA in CSF associated with listeria meningitis
20) Confidence 0.30 Published 2009 Journal Rinsho Shinkeigaku Section Abstract Doc Link 19928691 Disease Relevance 0.79 Pain Relevance 0.12

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox